"name","uuid:ID","label","id","rationale","description","instanceType"
"Study Design 1","c5ca7fb9-b2f7-4e01-91ac-d6fd799f3af0","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign"
